ERBB2 and breast carcinoma: As shown in Figure 1A and 1B, we observed considerable variability in the sensitivity of breast cancer cell lines to AICAR treatment, with breast cancer cell lines known to have high expression of HER2 (associated with gene amplification) or EGFR consistently showing greater sensitivity than cell lines without activation of either of these related receptor kinase subunits.